As of Friday close, Altimmune Inc.’s (NASDAQ:ALT) stock was down -$0.04, moving down -1.49 percent to $2.65. The average number of shares traded per day over the past five days has been 1,021,800 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.36 fall in that time frame. In the last twenty days, the average volume was 1,282,700, while in the previous 50 days, it was 1,904,588.
Since last month, ALT stock retreated -16.67%. Shares of the company fell to $2.63 on 08/18/23, the lowest level in the past month. A 52-week high of $23.49 was reached on 01/13/23 after having rallying from a 52-week low of $2.65. Since the beginning of this year, ALT’s stock price has dropped by -83.89% or -$13.80, and marked a new high 3 times. However, the stock has declined by -88.72% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ALT stock investors should be aware that Altimmune Inc. (ALT) stock had its last reported insider trading activity 4 days ago on Aug 15. Drutz David, the Director of the company, purchased of 300 shares for $2.88 on Aug 15. It resulted in a $862 investment by the insider. Eisenstadt Richard I added 10,000 shares at an average price of $4.31 on Mar 24. The insider now owns 22,010 shares following the transaction. On Mar 23, Chief Medical Officer Harris Matthew Scott bought 10,000 shares at $4.22 apiece. The transaction was valued at $42,200.
Financial Health
In the three months ended June 29, Altimmune Inc.’s quick ratio stood at 11.60, while its current ratio was 11.60, showing that the company is able to pay off its debt. Based on annual data, ALT earned $87.67 million in gross profit and brought in $68000.0 in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ALT’s revenue fell -3300.0% during the quarter, while net income inched up to $10000.0. While analysts expected Altimmune Inc. to report -$0.46 quarterly earnings, the actual figure was -$0.32 per share, beating the consensus estimate by 30.40%. During the quarter, the company generated -$18.51 million in EBITDA. The liabilities of Altimmune Inc. were 15.6 million at the end of its most recent quarter ended June 29, and its total debt was $0.9 million. The value of shareholders’ equity is $52.69 million.
Technical Picture
This quick technical analysis looks at Altimmune Inc.’s (ALT) price momentum. With a historical volatility rate of 32.45%, the RSI 9-day stood at 23.44% on 18 August.
With respect to its five-day moving average, the current Altimmune Inc. price is down by -11.96% percent or -$0.36. At present, ALT shares trade -15.61% below its 20-day simple moving average and -45.02% percent below its 100-day simple moving average. However, the stock is currently trading approximately -35.37% below its SMA50 and -78.87% below its SMA200.
Stochastic coefficient K was 4.85% and Stochastic coefficient D was 6.55%, while ATR was 0.18. Given the Stochastic reading of 2.70% for the 14-day period, the RSI (14) reading has been calculated as 28.23%. As of today, the MACD Oscillator reading stands at -0.19, while the 14-day reading stands at -0.27.
Analyst Ratings
Altimmune Inc. downgraded its rating on Altimmune Inc. (NASDAQ: ALT) to a Neutral in a note to investors on March 22, 2023. The analysts firm previously had a Buy rating on the stock.Altimmune Inc. (ALT) has been rated Buy by analysts. According to 0 brokerage firms, ALT is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Altimmune Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $17.00, the current consensus forecast for the stock is $6.00 – $35.00. Based on these forecasts, analysts predict Altimmune Inc. (ALT) will achieve an average price target of $19.38.
